Vancomycin ready to infuse - Hikma Pharmaceuticals
Alternative Names: TYZAVAN; Vancomycin ready-to-infuse - Hikma PharmaceuticalsLatest Information Update: 11 Dec 2025
At a glance
- Originator Hikma Pharmaceuticals
- Class Antibacterials; Glycopeptides; Peptide antibiotics
- Mechanism of Action Cell wall inhibitors
-
Orphan Drug Status
No
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Marketed Bacterial endocarditis; Bone and joint infections; Respiratory tract infections; Sepsis; Skin and soft tissue infections
Most Recent Events
- 08 Dec 2025 Launched for Bacterial endocarditis (In adolescents, In children, In the elderly, In infants, In adults) in USA (IV)
- 08 Dec 2025 Launched for Bone and joint infections (In adolescents, In children, In the elderly, In infants, In adults) in USA (IV)
- 08 Dec 2025 Launched for Respiratory tract infections (In adolescents, In children, In the elderly, In infants, In adults) in USA (IV)